Cash, cash equivalents and marketable securities were $420.0 million as of December 31, 2024, compared to $352.0 million as of December 31, 2023. The increase was primarily a result of the approximately $100 million registered direct offering completed in June of 2024 and the receipt of the $75 million payment for the clinical advancement milestone for VX-670 that was achieved in the first quarter of 2024, offset by cash used to fund operations. Based on current operating plans, the Company believes that its cash, cash equivalents and marketable securities as of December 31, 2024 will be sufficient to fund its operations into the second quarter of 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics Receives Buy Rating Amid Regulatory Progress and Promising Clinical Developments
- Optimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials
- Entrada Therapeutics Receives FDA Approval for DMD Study
- Entrada announces FDA removal of clinical hold on ENTR-601-44
- Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks